ORGANIZATION

October 2019 Drug Price Revision a Relief for JPMA: Official

December 25, 2018
The government’s decision to carry out an ad-hoc drug price revision tied to the consumption tax hike - both downward and upward price tweaks - at one time in October 2019 came as a relief for the Japan Pharmaceutical Manufacturers…

To read the full story

ORGANIZATION

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…